SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 9, 2017
RENNOVA HEALTH, INC.
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
|(Commission File Number)||(I.R.S. Employer Identification No.)|
|400 S. Australian Avenue, Suite 800, West Palm Beach, Florida||33401|
|(Address of Principal Executive Offices)||(Zip Code)|
|(Registrant’s Telephone Number, Including Area Code)|
|(Former Name or Former Address, if Changed Since Last Report)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|o||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|o||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|o||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|o||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed in its Form 8-K filed on September 14, 2016, on September 13, 2016, Nasdaq granted Rennova Health, Inc. (the “Company”) a 180-day extension, or until March 13, 2017, to regain compliance with the minimum $1.00 per share requirement for continued inclusion under Nasdaq Listing Rule 5550(a)(2) (the “Rule”). On March 9, 2017, the Company received a letter from Nasdaq notifying the Company that it has regained compliance with the Rule. The letter noted that the closing bid price of the Company’s common stock has been in excess of the $1.00 minimum requirement for the last 10 consecutive trading days from February 23 to March 8, 2017. As a result, Nasdaq considers the matter closed.
On March 10, 2017, the Company issued a press release that it has regained compliance with the Rule. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
|99.1||Press release dated March 10, 2017|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: March 10, 2017||RENNOVA HEALTH, INC.|
|By: /s/ Seamus Lagan|
|Chief Executive Officer|
|(principal executive officer)|
|Exhibit No.||Exhibit Description|
|99.1||Press Release dated March 10, 2017|